Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 3.8 %

Shares of NASDAQ:EVOK opened at $4.33 on Wednesday. The firm’s 50 day moving average is $5.15 and its two-hundred day moving average is $5.46. The firm has a market capitalization of $6.43 million, a P/E ratio of -0.39 and a beta of 0.36. Evoke Pharma has a 52 week low of $3.54 and a 52 week high of $17.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.